21
Feb
2022
15:30
GMT
16:30
CET
Live Stream
Cardiac Issues in Prostate Cancer
-
Views:
3848
-
Likes:
13
Overview
The treatment of prostate cancer can have a significant detrimental impact on the cardiovascular system. So, when is the right time for the oncologist to call the cardiologist – before, during or after treatment or maybe at all the timepoints?
This 45 minute broadcast with 10 minute live Q&A is presented by Dr Mark Linch (UCLH, London, UK) and Dr Darryl Leong (McMaster University, CA) with Dr Arjun Ghosh (Barts, London, UK) as moderator. It will examine the cardiovascular issues related to contemporary prostate cancer management and the evidence base for screening, prevention and managing cardiotoxicity. The panel will explain the importance of a team-based true cardio-oncology approach to treating this patient population.
Faculty:
Arjun K Ghosh
Darryl Leong
Mark Linch
Agenda
Key Learning Objectives
- Understand how a team-based cardio-oncology approach can improve cancer and cardiac outcomes for prostate cancer patients.
- Understand the current evidence base for managing cardiac issues in prostate cancer patients.
Audience
- Cardio-oncology specialists
- Medical and Clinical Oncologists
- Cardiologists
Faculty Biographies
Mark Linch
Dr Mark Linch is an Associate Professor at University College London (UCL) Cancer Institute, where he leads the Urological Cancer Biology Group, and Honorary Consultant Medical Oncologist.
Dr Linch trained in medical oncology at the Royal Marsden Hospital (RMH), London. In 2012 he was awarded a PhD in Cancer Cell Biology from UCL and the Cancer Research UK London Research Institute (LRI), now known as the Francis Crick Institute. He continued his post-doctoral studies at the LRI while also working as a Consultant Medical Oncologist at RMH.
In 2014 Dr Linch moved to UCL to specialise in the clinical management and translational biology of prostate and bladder cancer. His research is focused on the immune biology of these cancers with a view to identifying rational immunotherapy combinations, predictive biomarkers and novel liquid biopsy strategies. He is chief investigator of a number national and international combination immunotherapy trials in bladder and prostate cancer (DURANCE, NEPTUNES, Pro-MERIT), is Chair of the UK Prostate Cancer 100,000 genome project group and is an inaugural member of the UK Bladder Cancer Translational Group. He is funded by the NIHR/BRC, CRUK, Rosetrees Trust, Prostate Cancer Foundation, Prostate Cancer UK and Sir Peter Wood.
Darryl Leong
Dr Darryl Leong is Director of the Cardio-Oncology Program at Hamilton Health Sciences, and an Associate Professor of the Department of Medicine at McMaster University. He graduated from the University of Adelaide Medical School with honors for academic excellence, and completed his training in Cardiology, Doctor of Philosophy, Master of philosophy, Master of Biostatistics and Master of Public Health at the University of Adelaide. He then went on to complete his post-doctorate fellowship at the Leiden University Medical Centre in The Netherlands, studying cardiovascular imaging.
Dr Leong's clinical interests include cardio-oncology, echocardiography, frailty, and multi-morbidity.
Dr Leong has received research support from CIHR, the Heart and Stroke Foundation of Canada, Prostate Cancer Canada, the Canadian Cancer Society, the Cancer research society, and the Juravinski Hospital and Cancer Research Foundation.
Arjun K Ghosh
Dr Arjun Ghosh MBBS, MSc, PhD, FHEA, FACC, FESC, FRCP, FICOS is a Consultant Cardiologist at University College London Hospital (UCLH) and Barts Heart Centre, London, UK.
He helped establish and grow cardio-oncology services at UCLH and Barts Heart Centre which are now amongst the biggest in the world. He is the clinical lead of the UCLH service which looks after all the cardiac needs of cancer patients and also has national and international cardio-oncology leadership roles with the British Cardio-Oncology Society and the International Cardio-Oncology Society. Arjun was also joint first author of the UK’s first cardio-oncology guideline.